Evidence map›Paper›PMID 28363320›Full record

Trial reportDrug and alcohol dependence2017

The Prescription Opioid Addiction Treatment Study: What have we learned.

Roger D Weiss, Vinod Rao

Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Advancing emergency department-initiated buprenorphine.Journal of the American College of Emergency Physicians open · 2021
    Article
  18. Article
  19. Review
  20. Effect of Heroin on Electrocardiographic Parameters.Arquivos brasileiros de cardiologia · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Roger D WeissDivision of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: rweiss@mclean.harvard.edu.
Vinod RaoDepartment of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Partners HealthCare Addiction Psychiatry Fellowship, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: vinod.rao@mgh.harvard.edu.
Mass General Brigham · USMcLean Hospital · US

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Mentoring in Drug Abuse and Dual Diagnosis ResearchK24DA022288 · NIDA · MCLEAN HOSPITAL · PI WEISS, ROGER D. · 2007 to 2016
$1.8M
NIDA NIH HHS K24 DA022288NIDA NIH HHS UG1 DA015831
6 · The paper itself

Abstract

backgroundThe multi-site Prescription Opioid Addiction Treatment Study (POATS), conducted by the National Drug Abuse Treatment Clinical Trials Network, was the largest clinical trial yet conducted with patients dependent upon prescription opioids (N=653). In addition to main trial results, the study yielded numerous secondary analyses, and included a 3.5-year follow-up study, the first of its kind with this population. This paper reviews key findings from POATS and its follow-up study.

methodsThe paper summarizes the POATS design, main outcomes, predictors of outcome, subgroup analyses, the predictive power of early treatment response, and the long-term follow-up study.

resultsPOATS examined combinations of buprenorphine-naloxone of varying duration and counseling of varying intensity. The primary outcome analysis showed no overall benefit to adding drug counseling to buprenorphine-naloxone and weekly medical management. Only 7% of patients achieved a successful outcome (abstinence or near-abstinence from opioids) during a 4-week taper and 8-week follow-up; by comparison, 49% of patients achieved success while subsequently stabilized on buprenorphine-naloxone. Long-term follow-up results were more encouraging, with higher abstinence rates than in the main trial. Patients receiving opioid agonist treatment at the time of follow-up were more likely to have better outcomes, though a sizeable number of patients succeeded without agonist treatment. Some patients initiated risky use patterns, including heroin use and drug injection. A limitation of the long-term follow-up study was the low follow-up rate.

conclusionsPOATS was the first large-scale study of the treatment of prescription opioid dependence; its findings can influence both treatment guidelines and future studies.

Indexed as

Prescription Drug MisuseAdultAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationCombined Modality TherapyCounselingFollow-Up StudiesHeroin DependenceHumansMaleMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationAddictionFollow-upOpioid use disorderOutcomePrescription opioidsTreatment

Identifiers

PMID28363320
PMCPMC6866670
OpenAlexW2598776491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.